SCHEMBL4083881

SCHEMBL4083881

CC(C)(C)NCC(=O)NN

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.42
KDM4E B2RXH2 4/20 0.37
KDM5C P41229 1/20 0.37
PHF8 Q9UPP1 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37
DPP4 P27487 3/20 0.35
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GLA P06280 1/20 0.33
PKM P14618 1/20 0.33
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
AOC2 O75106 1/20 0.32
KDM6B O15054 1/20 0.31
KDM4A O75164 1/20 0.31
KDM5A P29375 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3404618 0.77 MCL1 (0.37) KDM4EDPP4ALDH1A1LMNAGLA
SCHEMBL10101586 0.77 MAPT (0.39) DPP4ALDH1A1LMNAGAADPP8
SCHEMBL21891278 0.75 MCL1 (0.45) CTSDALDH1A1LMNAGAAMEN1
SCHEMBL2161044 0.75 DPP4 (0.33) DPP4
SCHEMBL1908529 0.74
SCHEMBL10245280 0.73 MCL1 (0.41) KDM4EDPP4ALDH1A1GAAMEN1
SCHEMBL41886 0.73
SCHEMBL1717828 0.73 HMGCR (0.41) KDM4EDPP4ALDH1A1LMNADPP8
SCHEMBL24116324 0.72 EPHX1 (0.36) CTSD
SCHEMBL18272883 0.71 MEN1 (0.34) DPP4ALDH1A1MEN1KMT2ADPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CTSD 4644/4885KDM4E 3468/4885KDM5C 3014/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CTSD 4643/4885KDM4E 3359/4885KDM5C 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.